张

张如意 (Ruyi Zhang)

Jiangnan University未定职

H指数:26

被引数:5,236

个人简介

"张如意，2023年11月毕业于荷兰鹿特丹伊拉斯姆斯大学（Erasmus University Rotterdam）, 基础医学专业，获理学博士学位。2024年9月，进入云南民族大学从事教学及科研工作，主要研究领域为肿瘤分子生物学（Crispr/Cas9 基因编辑）、肿瘤与免疫、抗病毒治疗等方面。参与发表SCI论文10余篇，其中以第一作者在PNAS（中科院1区Top）、Cancer Research（中科院1区Top）、Liver International（中科院2区Top）等发表SCI论文5篇。\n研究方向及硕士研究生招生专业\n1.研究方向肿瘤分子生物学（Crispr/Cas9 基因编辑）、肿瘤与免疫、抗病毒治疗以及药理方面等2.硕士研究生招生专业分析化学、有机化学等相关专业\n科研项目\n无\n教学工作\n承担课程：承担食品化学、生物化学等课程。\n主持教学项目\n近三年学术成果\n代表性论文：1. Zhang, R, Peppelenbosch Maikel P., Smits Ron, et al. Analysis of tumor-associated AXIN1 missense mutations identifies variants that activate β-catenin signaling. Cancer Research. 2024 Feb 15.(中科院一区top， IF:11.2)2. Li, Y.#, Zhang, R.#, et al. (2023). Hepatitis E virus infection remodels the mature tRNAome in macrophages to orchestrate NLRP3 inflammasome response. Proc Natl Acad Sci U S A, 120(25), e2304445120.(# equal contribution,中科院一区top，IF:12.8)3. Zhang, R, Noordam, L, Ou, X, et al. The biological process of lysine-tRNA charging is therapeutically targetable in liver cancer. Liver International. 2021;41: 206– 219. (中科院二区， IF: 8.75).4. Zhang, R, Hornung Bastian V. H., van den Hout Mirjam C. G. N., van Ijcken Wilfred F. J., Peppelenbosch Maikel P., Smits Ron. Unraveling the impact of AXIN1 mutations on HCC development: Insights from CRISPR/Cas9 repaired AXIN1-mutant liver cancer cell lines. PLOS ONE, 2024, 19(6).5. Ou X#, Ma B#, Zhang R#, Miao Z, Cheng A, Peppelenbosch MP, Pan Q. A simplified qPCR method revealing tRNAome remodeling upon infection by genotype 3 hepatitis E virus. FEBS Lett. 2020 Jun; 594(12): 2005-2015. (# equal contribution)6. Li Y, Miao Z, Li P, Zhang R, Kainov DE, Ma Z, de Man RA, Peppelenbosch MP, Pan Q. Ivermectin effectively inhibits hepatitis E virus replication, requiring the host nuclear transport protein importin α1. Arch Virol. 2021 Jul;166(7):2005-2010.7. Wang W, Liu P, Lavrijsen M, Li S, Zhang R, Li S, van de Geer WS, van de Werken HJG, Peppelenbosch MP, Smits R. Evaluation of AXIN1 and AXIN2 as targets of tankyrase inhibition in hepatocellular carcinoma cell lines. Sci Rep. 2021 Apr 2;11(1):7470.8. Liu J, Li P, Zhang R, Zhou G, Carrascosa LC, Sprengers D, IJzermans JNM, Smits R, Kwekkeboom J, van der Laan LJW, Peppelenbosch MP, Pan Q, Cao W. Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance. Cell Mol Gastroenterol Hepatol. 2021;11(2):407-431.9. Li Y, Li P, Li Y, Zhang R, Yu P, Ma Z, Kainov DE, de Man RA, Peppelenbosch MP, Pan Q. Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation. Antiviral Res. 2020 Dec;184:10496710. Jiaye Liu, Dave Sprengers, Ruyi Zhang, Guoying Zhou, Ron Smits, Jaap Kwekkeboom, Luc J.W. van der Laan, Maikel Peppelenbosch, Qiuwei Pan, Wanlu Cao.FRI488 - Modelling liver tumor organoids and cancer-associated fibroblasts interaction reveals the robust effects of stromal niche in cancer nurturing and treatment resistance. Journal of Hepatology. 2020; 73(1):S638-S6311. Li P, Li Y, Wang Y, Liu J, Lavrijsen M, Li Y, Zhang R, Verstegen MMA, Wang Y, Li TC, Ma Z, Kainov DE, Bruno MJ, de Man RA, van der Laan LJW, Peppelenbosch MP, Pan Q. Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids. Sci Adv. 2022 Jan 21;8(3):eabj5908.12. Li Y, Li P, He Q, Zhang R, Li Y, Kamar N, Peppelenbosch MP, de Man RA, Wang L, Pan Q. Niclosamide inhibits hepatitis E virus through suppression of NF-kappaB signalling. Antiviral Res. 2022 Jan;197:105228.13. Gao K, Zong H, Hou K, Zhang Y, Zhang R, Zhao D, Guo X, Luo Y, Jia S. p53N236S Activates Autophagy in Response to Hypoxic Stress Induced by DFO. Genes (Basel). 2022 Apr 26;13(5):763\n专利\n获奖与荣誉\n2018年-2023年获得中国国家留学基金委员会博士奖学金（no. 201808530490）。"